Information Provided By:
Fly News Breaks for July 30, 2019
CRSP
Jul 30, 2019 | 05:49 EDT
Barclays analyst Gena Wang raised her price target for Crispr Therapeutics to $62 from $59 saying the company yesterday disclosed "encouraging" efficacy signs for CTX001. The analyst continues to believe initial data from CTX001 will validate the platform and generate potential upside. She now has higher confidence in CTX001 and reiterates an Overweight rating on Crispr Therapeutics.
News For CRSP From the Last 2 Days
CRSP
Apr 23, 2024 | 08:08 EDT
Meeting to be held in San Francisco on April 24 hosted by Mizuho.
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.